文献速递肝病

肝脏FGF21介导利拉鲁肽在饮食挑战小鼠中的功能

Hepatic Fibroblast Growth Factor 21 Is Involved in Mediating Functions of Liraglutide in Mice With Dietary Challenge.
PubMed 文献 · Hepatology · 2021-08-30

该研究在小鼠和原代肝细胞中探究利拉鲁肽对肝脏FGF21表达的刺激作用及GLP-1R involvement,并明确FGF21是否介导利拉鲁肽的部分功能。结果表明利拉鲁肽刺激肝脏Fgf21表达可能需要肝外器官的GLP-1R,且肝脏FGF21是利拉鲁肽降低体重和改善肝脏脂质稳态所必需的。

要点

  • 利拉鲁肽刺激小鼠肝脏Fgf21表达,但原代肝细胞直接处理无此效应。
  • 利拉鲁肽的减重和改善肝脏脂质稳态作用需要肝脏FGF21。
  • 利拉鲁肽刺激肝脏Fgf21表达可能需要肝外器官表达GLP-1R。

核心结论

  • 利拉鲁肽刺激的肝脏Fgf21表达可能需要肝外器官表达GLP-1R。
  • 肝脏FGF21是利拉鲁肽降低体重和改善肝脏脂质稳态所必需的。

研究设计与样本

  • 研究评估了每日注射利拉鲁肽3天的小鼠或直接接受利拉鲁肽处理的小鼠原代肝细胞中肝脏FGF21表达。
  • 在高脂饮食喂养小鼠中比较利拉鲁肽与西格列汀的效果,并在Glp1r-/-小鼠和肝脏特异性FGF21敲除(lFgf21-KO)小鼠中进行动物实验。

主要发现

  • 在野生型小鼠肝脏RNA测序和定量逆转录PCR中,观察到利拉鲁肽刺激肝脏Fgf21表达且缺乏Glp1r表达。
  • 在小鼠原代肝细胞中,利拉鲁肽未刺激Fgf21。
  • 在高脂饮食诱导肥胖小鼠中,利拉鲁肽或西格列汀治疗降低血浆甘油三酯水平,但减少体重增加的效果不同。
  • 利拉鲁肽治疗小鼠肝脏FGF21表达增加,而西格列汀治疗小鼠未观察到。
  • 在高脂饮食喂养的Glp1r-/-小鼠中,利拉鲁肽未显示有益效果且不能刺激Fgf21表达。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Several studies have shown that expression of hepatic fibroblast growth factor 21 (FGF21) can be stimulated by glucagon-like peptide 1 (GLP-1)-based diabetes drugs. As GLP-1 receptor (GLP-1R) is unlikely to be expressed in hepatocytes, we aimed to compare such stimulation in mice and in mouse hepatocytes, determine the involvement of GLP-1R, and clarify whether FGF21 mediates certain functions of the GLP-1R agonist liraglutide. APPROACH AND RESULTS: Liver FGF21 expression was assessed in mice receiving a daily liraglutide injection for 3 days or in mouse primary hepatocytes (MPHs) undergoing direct liraglutide treatment. The effects of liraglutide on metabolic improvement and FGF21 expression were then assessed in high-fat diet (HFD)-fed mice and compared with the effects of the dipeptidyl-peptidase 4 inhibitor sitagliptin. Animal studies were also performed in Glp1r-/- mice and liver-specific FGF21-knockout (lFgf21-KO) mice. In wild-type mouse liver that underwent RNA sequencing and quantitative reverse-transcription PCR, we observed liraglutide-stimulated hepatic Fgf21 expression and a lack of Glp1r expression. In MPHs, liraglutide did not stimulate Fgf21. In mice with HFD-induced obesity, liraglutide or sitagliptin treatment reduced plasma triglyceride levels, whereas their effect on reducing body-weight gain was different. Importantly, increased hepatic FGF21 expression was observed in liraglutide-treated mice but was not observed in sitagliptin-treated mice. In HFD-fed Glp1r-/- mice, liraglutide showed no beneficial effects and could not stimulate Fgf21 expression. In lFgf21-KO mice undergoing dietary challenge, the body-weight-gain attenuation and lipid homeostatic effects of liraglutide were lost or significantly reduced. CONCLUSIONS: We suggest that liraglutide-stimulated hepatic Fgf21 expression may require GLP-1R to be expressed in extrahepatic organs. Importantly, we revealed that hepatic FGF21 is required for liraglutide to lower body weight and improve hepatic lipid homeostasis. These observations advanced our mechanistic understanding of the function of GLP-1-based drugs in NAFLD.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Liu D, Pang J, Shao W, et al. Hepatic Fibroblast Growth Factor 21 Is Involved in Mediating Functions of Liraglutide in Mice With Dietary Challenge. Hepatology. 2021. PMID: 33851458. doi:10.1002/hep.31856

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。